Topic: rheumatoid arthritis
Scientists have fingered IL-6—a cytokine Actemra targets—as a main culprit in dangerous immune overreaction among COVID-19 patients.
To launch its new rheumatoid arthritis pill Rinvoq, AbbVie is leading with a DTC campaign meant to empower patients to "take on" the disease.
AbbVie is pinning high hopes—up to $20 billion—on new launches Rinvoq and Skyrizi. A cost-effectiveness nod could help Rinvoq reach that lofty goal.
With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, another Incyte med is also looking for a win in that indication.
To set its rheumatoid arthritis candidate filgotinib apart from numerous rivals, Gilead has three priorities in mind for the launch.
Humira's best days may be past, but AbbVie could one day see $20 billion in combined sales for follow-ups Rinvoq and Skyrizi, CEO Rick Gonzalez said.
We may be focusing on our forecasts for the year ahead with today's issue, but here's some Friday news we thought you shouldn't miss.
AbbVie hopes its Allergan takeover will help it weather the storm of an aging Humira. Could the next-gen antipsychotic Vraylar be a solution?
Amgen signed a deal with PBM Abarca that ties reimbursement for its RA blockbuster Enbrel to patients' willingness to stick with the drug.
Despite lagging behind in sales, RA newcomer Rinvoq is becoming a darling among physicians—and an "AbbVie halo" could be driving those warm feelings.